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The role of genes in normal birth-weight variation is poorly understood, and it has been suggested that the genetic
component of fetal growth is small. Type 2 diabetes genes may inﬂuence birth weight through maternal genotype, by
increasing maternal glycemia in pregnancy, or through fetal genotype, by altering fetal insulin secretion. We aimed to
assess the role of the recently described type 2 diabetes gene TCF7L2 in birth weight. We genotyped the polymorphism
rs7903146 in 15,709 individuals whose birth weight was available from six studies and in 8,344 mothers from three
studies. Each fetal copy of the predisposing allele was associated with an 18-g (95% conﬁdence interval [CI] 7–29 g)
increase in birth weight ( ) and each maternal copy with a 30-g (95% CI 15–45 g) increase in offspring birthPp .001
weight ( ). Stratiﬁcation by fetal genotype suggested that the association was driven by maternal genotype55Pp 2.8# 10
(31-g [95% CI 9–48 g] increase per allele; corrected ). Analysis of diabetes-related traits in 10,314 nondiabeticPp .003
individuals suggested the most likely mechanism is that the risk allele reduces maternal insulin secretion (disposition
index reduced by ∼0.15 standard deviation; ), which results in increased maternal glycemia in pregnancy54Pp 1# 10
and hence increased offspring birth weight. We combined information with the other common variant known to alter
fetal growth, the 530GrA polymorphism of glucokinase (rs1799884). The 4% of offspring born to mothers carrying
three or four risk alleles were 119 g (95% CI 62–172 g) heavier than were the 32% born to mothers with none (for overall
trend, ), comparable to the impact of maternal smoking during pregnancy. In conclusion, we have identiﬁed57Pp 2# 10
the ﬁrst type 2 diabetes–susceptibility allele to be reproducibly associated with birth weight. Common gene variants can
substantially inﬂuence normal birth-weight variation.
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The role of genes in normal variation in birth weight is
poorly understood, and it has been suggested that the
genetic component of fetal growth in the general pop-
ulation is small.1–4 In contrast, the maternal intrauterine
environment, including maternal glucose tolerance, BMI,
and smoking, has a large impact on birth weight.5–8 How-
ever, the importance of these environmental factors does
not negate the role of common maternal or fetal gene
variants as determinants of normal fetal growth. Family,
twin, and linkage studies suggest a role for common ge-
netic variants,1,3,4,9–11 but, to date, speciﬁc genetic loci re-
main largely unknown.
Diabetes-susceptibility genes or genes that alter fasting
glucose are good candidates for genes that inﬂuence birth
weight, since they may impact insulin secretion or insulin
action in nondiabetic individuals. Altered fetal insulin se-
cretion would alter fetal growth and hence birth weight,
since insulin is a key intrauterine growth factor. A dia-
betes-risk allele in the mother may alter fetal growth in-
directly, by altering maternal glycemia during pregnancy
and thereby inﬂuencing fetal insulin secretion. Alterna-
tively, a diabetes-risk allele in the fetus may act directly
on fetal insulin secretion. Reduced birth weight is asso-
ciated with an increased risk of type 2 diabetes (MIM
125853) later in life,12,13 and it has been proposed under
the fetal insulin hypothesis that this association could
have a genetic explanation.14 There is some evidence of
this from population studies.15–18 Direct evidence that birth
weight is altered by fetal and maternal inheritance of di-
abetes-susceptibility genes is provided by several rare sub-
types of diabetes. These include mutations in monogenic
diabetes genes that reduce birth weight as a result of re-
duced fetal insulin secretion in utero19–24 and mutations
in other monogenic diabetes genes that increase birth
weight as a result of increased fetal insulin secretion.25
The observations inmonogenic diabetes and the general
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Table 1. Clinical Characteristics of Subjects Included in the Analysis of the TCF7L2 rs7903146 Genotype with Birth
Weight
Characteristic
Characteristics by Study
BCG EFSOCH NCCGP 1958BC NFBC1966 ALSPAC
Na (% male) 571 (52.2) 792 (52.9) 1,096 (49.9) 1,779 (49.5) 4,578 (47.7) 6,893 (51.2)
Mean (SD) birth weight, in g 3,387 (496) 3,504 (478) 3,441 (485) 3,351 (494) 3,536 (490) 3,489 (474)
Median (IQR) gestation, in wk 40.0 (39.0–41.0) 40.3 (39.3–41.1) 40.0 (39.041.0) 40.3 (39.4–41.3) 40.0 (38.0–42.0) 40.0 (39.0–41.0)
Median (IQR) maternal age, in years NA 31.0 (27.0–34.0) 28.8 (24.0–32.8) 27.0 (23.0–31.0) 27.2 (17.4–36.9) 29.0 (26.0–32.0)
Median (IQR) maternal prepregnancy BMIb NA 23.0 (21.1–25.7) NA 22.1 (20.4–24.5) 22.7 (18.9–26.5) 22.2 (20.5–24.4)
Primiparous births (%) NA 55.3 66.2 35.2 30.6 43.3
Maternal smoking during pregnancy (%) NA 13.8 26.0 32.9 13.4 19.9
NOTE.—The clinical characteristics of offspring with maternal rs7903146 genotype data available (917, 1,133, and 6,294 individuals from EFSOCH, NCCGP, and ALSPAC,
respectively) were very similar (data not shown). In some cases, offspring birth weight and maternal genotype were available, whereas offspring genotype was unavailable.
Therefore, for EFSOCH and NCCGP, the number of subjects in the maternal genotype analysis was larger than that included in the fetal genotype analysis. NApnot
available; IQRpinterquartile range.
a Includes white, singleton individuals, genotyped for rs7903146, with birth weight available, born at minimum gestation of 36 wk.
b Calculated as weight in kilograms divided by the square of height in meters.
population led to the hypothesis that inheritance of type
2 diabetes–susceptibility alleles by the fetus would reduce
birth weight, whereas their inheritance by the mother
would increase offspring birth weight. Some studies have
suggested that inheritance by the fetus of polymorphisms
associated with type 2 diabetes is associated with reduced
birth weight,26,27 but these results have not been repli-
cated.28–32 A maternal copy of the A allele of the common
glucokinase (GCK [MIM 138079]) promoter polymorphism
(GCK-30; rs1799884), which is associated with raised fast-
ing glucose at all ages in the general population (Pp
), is also associated with a 32-g (95% CI 11–53 g)91# 10
increase in offspring birth weight ( ). However,Pp .002
there is no evidence of an independent effect of fetal
genotype.33,34
The gene encoding transcription factor 7–like 2 (TCF7L2
[MIM 602228]) is the most important type 2 diabetes sus-
ceptibility gene found to date.35 Since its discovery, the
association has been replicated in subjects of U.K., Amish,
Finnish, French, U.S., Polish, Scandinavian, Dutch, Indian,
and West African origin.36–45 In the U.K. population, the
allelic odds ratio for rs7903146 (risk-allele frequency∼30%)
is 1.36 (95% CI 1.24–1.48; ), and individ-11Pp 1.3# 10
uals carrying two risk (T) alleles are at nearly twice the risk
of type 2 diabetes as are those with none.36 Studies of
nondiabetic subjects indicate that TCF7L2 diabetes-risk
genotypes alter insulin secretion.37,42,46 The impact of this
polymorphism on birth weight has not been studied.
In the present study, we hypothesized that fetal TCF7L2
type 2 diabetes–predisposing genotypes at rs7903146 and
rs12255372would be associatedwith reduced birthweight
and that maternal genotypes would be associated with
increased offspring birth weight through elevated mater-
nal glucose. We investigated this hypothesis in 124,000
individuals from six population-based studies. In addition,
we explored the role of these variants in diabetes-related
intermediate traits, including beta-cell function, in 110,000
young (median age 45 years), nondiabetic individuals
from ﬁve studies.
Subjects and Methods
Subjects for Analysis of Fetal TCF7L2 Genotype with Birth
Weight
To assess the association of fetal TCF7L2 genotypes with birth
weight, we used subjects from six studies (table 1). All subjects
were born at 36 full wk gestation or later and were of white
European origin, either from the United Kingdom (Barry Caer-
philly Growth Study [BCG],29 Exeter Family Study of Childhood
Health [EFSOCH],47 North Cumbria Community Genetics Project
[NCCGP],48 British 1958 Birth Cohort [1958BC],36,49 and Avon
Longitudinal Study of Parents and Children [ALSPAC]50) or Fin-
land (Northern Finland 1966 Birth Cohort [NFBC1966]).51–53
These studies have been described in depth elsewhere, but brief
details are as follows. BCG is a longitudinal study of individuals
born between 1972 and 1974 whose growth was monitored
from birth to age 5 years. Data for analysis of the association of
rs7903146 with birth weight were available for 571 subjects. EF-
SOCH is a prospective study of children, born between 2000 and
2004, and their parents from a geographically deﬁned region of
Exeter, United Kingdom. Data for 792 EFSOCH babies were avail-
able for the present analysis. Maternal fasting glucose, assessed
at 26–28 wk gestation, was available for these subjects. Maternal
smoking status was also assessed at that time. NCCGP is a com-
munity-based DNA-banking project. Data were available for 1,096
babies born between April 1999 andMarch 2002. Maternal smok-
ing status was assessed during the ﬁrst 12 wk of pregnancy. The
1958BC is a national cohort of U.K. subjects born during the same
week in March 1958. The 1,779 subjects included in the present
analysis are from the ﬁrst group of subjects from whom DNAwas
extracted during 2003–2005. Information about smoking during
pregnancy was reported by the mothers after the birth of the
child and was coded as smoking continuing after the 4th mo of
pregnancy (“yes/no”). ALSPAC is a prospective study, which re-
cruited pregnant women from Bristol, United Kingdom, with ex-
pected delivery dates between April 1991 and December 1992.
We were able to include 6,893 of the ALSPAC children in the
present analysis. Maternal smoking status was assessed during the
ﬁrst 12 wk of gestation. NFBC1966 is a study of offspring born
in the two northernmost provinces of Finland to mothers with
expected dates of delivery in 1966. The 4,578 subjects included
in the present analysis are from a subset of individuals who had
anthropometric data taken and DNA extracted at age 31 years.
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Table 2. Clinical Characteristics of Individuals Included in the Diabetes-Related Trait Analyses for the TCF7L2
rs7903146 Genotype
Characteristic
Characteristics by Study
BCG EFSOCH 1958BC NFBC1966 ALSPAC
Na (% male) 619 (52.8) 1,810 (49.1) 1,813 (49.7) 4,486 (46.3) 697 (53.8)
Median (IQRb) age, in years 25.0 (24.5–25.6) 31.0 (28.0–35.0) 45.0 31.0 8.0
Median (IQR) BMIc 24.3 (22.0–27.3) 24.8 (22.2–27.7)d 26.5 (23.9–29.8) 24.0 (19.2–28.8) 16.2 (15.2–17.6)
Median (IQR) fasting plasma:
Glucose, in mmol/liter 4.6 (4.3–4.8) 4.5 (4.2–4.8) NA 5.0 (4.5–5.5) 4.9 (4.7–5.1)
Insulin, in pmol/liter 39.6 (29.4–55.8) 54.8 (40.4–79.0) NA 52.1 (29.2–75.0) 33.3 (21.5–54.9)
HbA1c (IQR) [%] NA 5.1 (4.8–5.3) 5.2 (5.0–5.5) NA 4.9
e (4.7–5.1)
NOTE.—NApnot available; IQRpinterquartile range.
a Includes white, unrelated individuals genotyped for rs7901346. When information was available, subjects with diabetes, HbA1c
16%, or fasting plasma glucose 16 mmol/liter were excluded.
b IQR not applicable for 1958BC, NFBC1966, and ALSPAC, since participants were all studied at the same age.
c Calculated as weight in kilograms divided by the square of height in meters.
d Females were pregnant (28 wk gestation) at time of study, but BMI is the prepregnancy value.
e HbA1c was measured in 1,280 subjects at age 7 years (50.6% male), whereas all other data in this column were gathered 1 year
later. A total of 391 ALSPAC children were included at both times.
Maternal smoking status was assessed throughout the pregnancy
and was classiﬁed as “yes/no” after the 8th gestational wk.
Only singleton pregnancies were included in the analyses. In
all studies, birth weight was obtained from hospital records, and
gestation was inferred from the last menstrual period or ultra-
sound scan. In most studies, data were available on parity (di-
chotomized as ﬁrst child or subsequent), maternal prepregnancy
BMI, and maternal smoking status (smoking or nonsmoking dur-
ing pregnancy). All subjects involved gave their informed con-
sent, and ethical approval was obtained from the local institu-
tional review board for each study.
Subjects for Analysis of Maternal TCF7L2 Genotype
with Offspring Birth Weight
To assess the association of maternal TCF7L2 genotypes with off-
spring birth weight, we used a total of 8,344 genotyped mothers
from the three studies in which maternal DNA was available (917
from EFSOCH, 1,133 from NCCGP, and 6,294 from ALSPAC). Al-
together, there were 6,044 mother-offspring pairs with both
mother’s and child’s rs7903146 genotype and offspring birth
weight available (754 from EFSOCH, 1,024 from NCCGP, and
4,266 from ALSPAC). Maternal DNA was not available for BCG,
1958BC, or NFBC1966 subjects.
Subjects for Analysis of TCF7L2 Genotype
with Diabetes-Related Intermediate Trait Data
We investigated possible associations of TCF7L2 genotypes with
diabetes-related intermediate traits in the BCG, EFSOCH, 1958BC,
NFBC1966, and ALSPAC studies. Since the BCG, 1958BC, and
NFBC1966 studies are long-term follow-up cohorts, detailed quan-
titative trait data were available for the individuals as young
adults, in addition to their birth and early-life data. In the case
of ALSPAC, diabetes-related intermediate traits were measured in
subsets of children at ages 7 and 8 years. For EFSOCH, we used
data from the mothers and fathers. Again, analysis was restricted
to individuals of white European origin. In addition, when in-
formation was available, subjects with diabetes, fasting plasma
glucose 16 mmol/liter, or glycated hemoglobin (HbA1c) 16%were
excluded. The clinical characteristics of these subjects are shown
in table 2.
Oral glucose-tolerance test data were available for 619 BCG
adults and 697 ALSPAC children. These consisted of plasma glu-
cose and insulin measures taken after fasting and then repeated
30min after administration of an oral glucose load.We calculated
early insulin response to glucose54
Ins  fasting insulin30
Gluc30
and insulin disposition index (insulinogenic index # homeosta-
sis model assessment of insulin resistance [HOMA-IR]), where
Ins  fasting insulin30insulogenic indexp
Gluc  fasting glucose30
and42
fasting glucose# fasting insulin
HOMA-IRp .
22.5
Whereas early insulin response is a measure of insulin secretion,
disposition index is a corrected measure, accounting for an in-
dividual’s insulin resistance. Fasting-glucose and insulin data were
also available for 1,810 EFSOCH parents and 4,486 NFBC1966
adults. Using the online HOMA Calculator version 2.2 (available
from the Diabetes Trials Unit Web site) we obtained model-de-
rived estimates of HOMA-IR for these subjects. HbA1c was avail-
able for 1,280 ALSPAC children, 1,442 EFSOCHparents, and1,813
subjects from 1958BC. Finally, BMI was available for all subjects
and for 5,817 ALSPAC mothers.
Genotyping and Quality Control
The rs7903146 and rs12255372 polymorphisms were genotyped
in all cohorts. Genotyping was performed on the BCG, 1958BC,
EFSOCH, NFBC1966, and ALSPAC samples by KBiosciences, with
use of their own novel system of ﬂuorescence-based competitive
allele-speciﬁc PCR (KASPar). Details of assay design are available
from the KBiosciences Web site. Genotyping of the NCCGP sam-
ples was performed in-house (Peninsula Medical School), with
use of TaqMan SNP genotyping assay (Applied Biosystems) ac-
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cording to the manufacturer’s protocol. Additional EFSOCH sam-
ples (70 children and 104 parents) were genotyped in this way
for rs7903146. These genotypes were added to the genotypes from
KBiosciences, since the concordance for samples genotyped by
both centers ( ) was 98.9%.np 1,706
The percentage of successful genotype calls was 190% in all
groups, apart from NCCGP children (88% rs7903146; 89%
rs12255372). The percentage of duplicate samples included for
genotyping in each study group was 1% (1958BC), 3% (ALSPAC
children), 6% (ALSPAC mothers and NFBC1966), 10% (BCG and
EFSOCH), and 21% (NCCGP). Concordance between duplicate
samples was 99% in all groups except NFBC1966 (98.1%
rs7903146) and ALSPAC children (98.4% rs7903146). No devia-
tion from Hardy-Weinberg equilibrium was observed (all ).P 1 .05
The minor-allele frequency (MAF) of rs7903146 was 19.1% in
NFBC1966 and had a range of 29.0%–30.4% in the U.K. samples.
The MAF of rs12255372 was 16.8% in NFBC1966 and had a range
of 28.4%–29.8% in the U.K. samples. These ﬁgures are consistent
with those observed elsewhere in Finnish38 and U.K.36 subjects,
and the difference is therefore likely to reﬂect underlying differ-
ences in population allele frequencies than differences due to our
sampling or genotyping. The SNPs were in linkage disequilibrium
in all study groups (r2 range 0.74–0.79 in U.K. samples; 0.69 in
NFBC1966).
Statistical Analysis
We performed linear regression analysis within each study, with
birth weight as the dependent and SNP genotype (coded as zero,
one, or two risk alleles) as the independent variable and with sex
and gestation as covariates. We performed additional analyses
correcting also for parity, maternal smoking, maternal prepreg-
nancy BMI, and maternal fasting plasma–glucose concentration,
when these variables were available. All regression analyses were
performed using Stata SE version 9 (StataCorp) or SPSS version
11.5. We looked for evidence of deviation from an additive ge-
netic model in ALSPAC by comparing the full genotype model
with the additive model, using the likelihood-ratio test.We found
no evidence to reject the additive model ( ), so this wasP 1 .05
assumed for all regression analyses. Inverse variance meta-anal-
ysis (ﬁxed effects) statistics and plots were generated using Stats-
Direct version 2.5.6. The I2 (inconsistency) statistic was used to
estimate the proportion of variance attributable to between-study
heterogeneity.55 By performing a meta-analysis of summary data
from the separate studies, we were able to avoid the potential
confounding effect of the difference between the NFBC1966 and
U.K. allele frequencies. To investigate the relative contributions
to birth weight of maternal and fetal genotypes, we generated
standardized residuals from a regression of birth weight on sex
and gestation within the EFSOCH, NCCGP, and ALSPAC studies.
We combined these sex- and gestational age–corrected birth
weight Z scores ( ; ) into one data set. We thenmeanp 0 SDp 1
performed a regression analysis with birth-weight Z score as the
dependent and both maternal and fetal genotypes as indepen-
dent variables. Since there is a degree of colinearity between ma-
ternal and fetal genotype ( ), we performed stratiﬁed anal-r ≈ 0.5
yses to verify this result; within each of the three strata deﬁned
by maternal genotype, birth-weight Z score was regressed on fetal
genotype, then the three regression coefﬁcients were combined
using a meta-analysis approach (ﬁxed effects, inverse-variance
method). The same analysis was performed formaternal genotype
with data stratiﬁed by fetal genotype.
All diabetes-related trait variables, apart from fasting glucose,
required log transformation to obtain a normal distribution be-
fore analysis. Linear regression analyses were performed for each
trait against genotype (additive model). When appropriate, we
included age, sex, and ln(BMI) as covariates.
To investigate the combined effects of maternal TCF7L2
rs7903146 and GCK rs1799884 genotype on offspring birth
weight, we combined sex- and gestational age–corrected birth-
weight Z scores from the 6,122 ALSPAC and 737 EFSOCH subjects
for whom genotypes at both loci were available. We performed
a regression analysis with Z score as the independent variable and
“TCF7L2-GCK genotype” (values of zero, one, two, and three or
four maternal risk alleles) as the dependent variable. We com-
bined individuals with three or four risk alleles, because of small
numbers in the ﬁnal category. We looked for evidence of devia-
tion from an additive genetic model in the separate analyses of
birth-weight Z score versus TCF7L2 rs7903146 or GCK rs1799884
and, in the combined analysis, by comparing the full genotype
model with the additive model with use of the likelihood-ratio
test. We found no evidence to reject the additive model (all P 1
), so this was assumed for the combined analysis. The mean.4
birth-weight Z score of offspring born to mothers with no risk
alleles was compared with those born to mothers carrying three
or four risk alleles, with use of an independent-samples t test.
Power calculations were performed using Lenth’s Java Applets
for Power and Sample Size (available from the Russ Lenth’s Power
and Sample Size Web site), with the assumption of an MAF of
30%, birth-weight SD of 480 g, and a two-tailed . Our sam-P ! .05
ple of 15,709 subjects with available birth weight gave us 80%
power to detect differences of 39 g in birth weight between ho-
mozygotes. In assessment of the effect of maternal genotype, our
sample of 8,344 genotyped mothers gave us 80% power to detect
differences of 53 g between homozygotes.
Results
Association of Fetal TCF7L2 Genotype with Birth Weight
Since SNPs rs7903146 and rs12255372 are highly corre-
lated ( ), the results obtained for each were similar.2r ≈ 0.75
In this work, we focus on rs7903146, since that SNP is
associated more strongly with type 2 diabetes.36,45 Detailed
data for rs12255372 are available from the authors.
Meta-analysis of the association between birth weight
(corrected for sex and gestation) and fetal rs7903146 ge-
notype showed an 18-g (95% CI 7–29 g) increase in birth
weight per T allele ( ) (ﬁg. 1 and table 3). Hetero-Pp .001
geneity between studies was low ( ). The asso-2I p 21.0%
ciation observed with rs12255372 was similar (combined
per-allele g [95% CI 8–30 g]; ;differencep 19 Pp .0009
). The largest contribution to the overall effect size2I p 0%
was made by ALSPAC, the largest individual study. In that
study, fetal rs7903146 genotype was associated with in-
creased birth weight (per–T allele increase 23 g [95% CI
7–39 g]; ). Correction for other covariates of birthPp .004
weight made little difference to the results (data available
from the authors).
Table 3. Analysis of Birth Weight by Fetal TCF7L2 rs7903146 Genotype
Study
Total
N
CC CT TT
Per–T Allele
Birth-Weighta
Difference (SE)b
P
Mean Birth Weighta
(95% CI) n
Mean Birth Weighta
(95% CI) n
Mean Birth Weighta
(95% CI) n Uncorrected
Corrected for Sex
and Gestation
Corrected for Additional
Covariatesc
BCG 571 3,355 (3,301–3,409) 281 3,411 (3,352–3,471) 233 3,444 (3,324–3,564) 57 49 (29) .13 .10 NA
EFSOCH 792 3,475 (3,432–3,517) 399 3,523 (3,476–3,570) 316 3,583 (3,487–3,679) 77 52 (23) .11 .03 .05
NCCGP 1,096 3,455 (3,419–3,491) 542 3,412 (3,374–3,451) 467 3,505 (3,416–3,596) 87 4 (20) .38 .83 NA
1958BC 1,605 3,359 (3,327–3,392) 764 3,358 (3,324–3,392) 700 3,365 (3,290–3,440) 141 1 (18) .76 .96 .87
NFBC1966 4,578 3,534 (3,516–3,551) 2,978 3,541 (3,516–3,566) 1,444 3,540 (3,466–3,615) 156 9 (12) .66 .47 .52
ALSPAC 6,893 3,474 (3,460–3,489) 3,372 3,499 (3,483–3,515) 2,876 3,517 (3,483–3,550) 645 23 (8) .03 .004 .01
NOTE.—All weights are given in grams.
a Corrected for sex and gestation.
b Rounded to the nearest 1 g.
c Corrected for sex, gestation, parity (ﬁrst child/subsequent), maternal smoking (yes/no), and maternal prepregnancy BMI. NApnot available.
Table 4. Analysis of Offspring Birth Weight by Maternal TCF7L2 rs7903146 Genotype
Study
Total
N
CC CT TT
Per–T Allele
Birth-Weighta
Difference (SE)b
P
Mean Birth Weighta
(95% CI) n
Mean Birth Weighta
(95% CI) n
Mean Birth Weighta
(95% CI) n Uncorrected
Corrected for Sex
and Gestation
Corrected for Additional
Covariatesc
EFSOCH 917 3,471 (3,432–3,509) 460 3,488 (3,446–3,530) 384 3,549 (3,452–3,646) 73 30 (22) .25 .18 .34
NCCGP 1,133 3,439 (3,403–3,475) 563 3,448 (3,409–3,487) 470 3,434 (3,349–3,519) 100 2 (20) .39 .91 NAd
ALSPAC 6,294 3,443 (3,426–3,460) 3,051 3,491 (3,473–3,509) 2,702 3,494 (3,453–3,534) 541 35 (9) .0002 .00004 .00002
NOTE.—All weights are given in grams.
a Corrected for sex and gestation.
b Rounded to the nearest 1 g.
c Corrected for sex, gestation, parity (ﬁrst child/subsequent), maternal smoking (yes/no), and maternal prepregnancy BMI.
d NApnot available.
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Figure 1. Meta-analysis of the association of birth weight (cor-
rected for sex and gestation) with fetal rs7903146 genotype across
six studies, arranged in order of increasing size. The effect size
(in grams) and 95% CI per risk allele is presented. Combined per-
allele g (95% CI 7–29 g); ; .2differencep 18 Pp .001 I p 21.0%
Figure 2. Meta-analysis of the association of birth weight (cor-
rected for sex and gestation) with maternal rs7903146 genotype
across three studies, arranged in order of increasing size. The effect
size (in grams) and 95% CI per risk allele is presented. Combined
per-allele g (95% CI 15–45 g); .5differencep 30 Pp 2.8# 10
.2I p 14.3%
Association of Maternal TCF7L2 Genotype with Offspring
Birth Weight
Meta-analysis of the association between birth weight
(corrected for sex and gestation) and maternal rs7903146
genotype showed a 30-g (95%CI 15–45 g) increase in birth
weight per T allele ( ) (ﬁg. 2 and table5Pp 2.8# 10
4). Again, heterogeneity between studies was low
( ). The association observed with rs122553722I p 14.3%
was similar (combined per-allele g [95%differencep 29
CI 14–43 g]; ; ). Again, the largest5 2Pp 4.5# 10 I p 0%
individual study, ALSPAC, made the largest contribution
to the combined association. In ALSPAC, the maternal
rs7903146 genotype was associated with a per–T allele in-
crease in offspring birth weight of 35 g (95% CI 17–53 g;
). Correction for other covariates of birth5Pp 4# 10
weight again made little difference to the meta-analysis
result (data available from the authors).
Data on maternal diabetes status were variable and in-
complete across the cohorts, so no subject was excluded
from the main analysis on that basis. Data on diabetes
status were available for 96% of the ALSPAC mothers.
These mothers had been asked whether they had ever had
diabetes. Removal of the 64 mothers who had answered
“yes” from the analysis of offspring birth weight versus
maternal rs7903146 genotype, sex, and gestation did not
alter the results.
Adjustment of Fetal and Maternal Genotype Effects for One
Another
Maternal and fetal genotypes are 50% correlated. To es-
tablish whether maternal or fetal genotypes were driving
the association, we used 6,044 mother-offspring pairs for
whom both maternal and fetal rs7903146 genotypes were
available. Regression of birth-weight Z score on fetal and
maternal genotype revealed an association of maternal
(per–T allele increase 0.07 [95% CI 0.02–0.11]; )Pp .003
but not fetal (per–T allele increase 0.02 [95% CI 0.02 to
0.07]; ) genotype with birth weight. Stratiﬁed anal-Pp .29
yses conﬁrmed this result. With use of the SD of birth
weight (440 g), corrected for sex and gestation, in ALSPAC
children with genotyped mothers, the effect size of 0.07
(95% CI 0.02–0.11) Z scores is equivalent to an increase
of 31 g (9–48 g) per maternal T allele. The results of this
analysis for rs12255372 were similar: there was an asso-
ciation of maternal (per–T allele increase 0.05 [95% CI
0.01–0.10]; ) but not fetal (per–T allele increasePp .025
0.03 [95% CI 0.01 to 0.08]; ) genotype with birthPp .16
weight.
Combined Analysis of Maternal TCF7L2 and GCK Genotype
with Offspring Birth Weight
A previous study showed that maternal genotypes of the
glucokinase (GCK) variant rs1799884 (GCK-30) are repro-
ducibly associated with offspring birth weight.33,34 To as-
sess the combined effect of maternal TCF7L2 rs7903146
and GCK rs1799884 variants on birth weight, we used the
737 EFSOCH and 6,122 ALSPAC subjects for whom ma-
ternal genotype was available at both loci. In this data set,
maternal GCK rs1799884 genotype was associated with a
per–A allele increase in offspring birth-weight Z score of
0.06 (95% CI 0.02–0.10; ; ∼27 g [95% CI 8–46 g]).Pp .006
This is similar to the effect size observed in the present
study for TCF7L2 rs7903146. We analyzed sex- and ges-
tational age–corrected birth-weight Z score against the
number of TCF7L2 rs7903146 and GCK rs1799884 mater-
nal risk alleles (zero, one, two, and three or four) in 6,859
individuals (ﬁg. 3). We conﬁrmed that it was valid to com-
bine data from the two polymorphisms in this way, be-
cause there was no deviation from an additive model
( ). The addition of each maternal allele (or alleles)Pp .53
was associated with an increase in Z score of 0.08 (95%
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Figure 3. Bar graph showing sex- and gestational age–corrected birth-weight Z score plotted against the number of maternal risk
alleles for TCF7L2 rs7903146 and GCK rs1799884. Error bars show 95% CIs.
CI 0.05–0.10; ). This equates to a per-allele7Pp 2# 10
increase of 35 g (95% CI 22–44 g). Offspring born to the
4% of mothers with three or four risk alleles had a 0.27
(95% CI 0.14–0.39) higher birth-weight Z score than those
born to the 32% of mothers with no risk alleles (Pp
), which equates to a difference of 119 g (95% CI53# 10
62–172 g).
Association of TCF7L2 Genotypes with Diabetes-Related
Intermediate Traits
To help establish the mechanism through whichmaternal
TCF7L2 genotype may be altering birth weight, we an-
alyzed a number of type 2 diabetes–related continuous
traits in 10,314 subjects. The results of the intermediate
trait analysis for rs7903146 are shown in table 5. The type
2 diabetes–risk allele (T) was associated with a reduction
in insulin secretion in the BCG and ALSPAC studies, as
measured by early-insulin response (combined per–T allele
decrease [logged data]0.067 [95%CI0.118 to0.016];
; ) and insulin-disposition index (com-Pp .02 np 1,235
bined per–T allele decrease [logged data] 0.192 [95% CI
0.288 to 0.096]; ; ). An associ-4Pp 1# 10 np 1,184
ation was also seen with increased fasting plasma glucose
across the BCG, EFSOCH, ALSPAC, and NFBC1966 studies
(combined per–T allele increase 0.020 mmol/liter [95% CI
0.005–0.035 mmol/liter]; ; ; ).2Pp .01 np 7,612 I p 9.2%
After a Bonferroni correction for the six studied traits was
applied, the early-insulin response and fasting-glucose as-
sociations did not remain at . However, the corre-P ! .05
lation between these traits means that this is a conserva-
tive correction, and there is insufﬁcient statistical power to
rule out the associations observed. Whereas the rs7903146
T allele was associated with reduced fasting insulin and
HOMA-IR in the BCG cohort ( ), this associationwasP ! .05
not seen in the two larger cohorts ( ). No associationP 1 .1
was observed between the TCF7L2 genotype and HbA1c
( ). There was no evidence of association of TCF7L2P 1 .05
genotype with BMI in any cohort (all ) (data notP 1 .05
shown). The results of the analyses for rs12255372 were
similar (data available from the authors).
Discussion
Using a total of 24,053 subjects from six studies, we have
shown that TCF7L2 is the ﬁrst type 2 diabetes gene to be
reproducibly associated with altered birth weight. Each
maternal copy of the T allele at rs7903146 increased off-
spring birth weight by 30 g (95% CI 15–45 g), and our
data suggest that the most likely mechanism is through
reduced maternal-insulin secretion resulting in mater-
nal hyperglycemia and increased insulin-mediated fetal
growth.
The understanding of the regulation of birth weight is
important, not only because of direct effects of high or
low birth weight on perinatal mortality and morbidity,
but also because of the association of altered birth weight
with altered adult phenotypes. It has been proposed under
the fetal-insulin hypothesis that diabetes-susceptibility al-
leles might reduce birth weight by reducing fetal insulin
secretion or action.14 Our results do not support this hy-
pothesis for TCF7L2, since we found an increase and not
a reduction in birth weight with fetal inheritance of the
type 2 diabetes risk allele. Our analysis of mother-child
pairs suggests that the increase seen in the offspring is not
a direct effect of the fetal risk allele but, rather, is a re-
ﬂection of its presence in the mother.
There was clear evidence in support of the hypothesis
that the presence of a maternal type 2 diabetes–suscepti-
bility allele would result in increased offspring birthweight.
Maternal TCF7L2 risk genotypes increase birth weight by
Table 5. Type 2 Diabetes–Related Intermediate Trait Analyses for the TCF7L2 rs7903146 Genotype
Trait (units) and Study N
Uncorrected Mean (95% CI)
Per–T Allele Trait
Difference (SE)
P
CC CT TT Uncorrected Correcteda
Fasting plasma glucose (mmol/liter):
BCG 619 4.61 (4.57–4.65) 4.61 (4.56–4.66) 4.56 (4.47–4.66) .016 (.023) .48 .72
ALSPAC 697 4.92 (4.88–4.96) 4.92 (4.90–4.95) 4.96 (4.88–5.03) .012 (.019) .52 .53
EFSOCH 1,810 4.49 (4.46–4.52) 4.55 (4.52–4.58) 4.52 (4.44–4.59) .031 (.016) .06 .08
NFBC1966 4,486 4.98 (4.96–4.99) 4.99 (4.97–4.99) 5.03 (4.97–5.09) .025 (.011) .03 .06
Combined 7,612 .020 (.008) .01 .03
Fasting plasma insulin (pmol/liter):
BCG 619 42.8 (40.4–45.4) 40.9 (38.3–43.5) 35.7 (31.5–40.4) .076 (.031) .02 .002
ALSPAC 697 37.2 (34.5–40.0) 34.8 (33.5–37.6) 35.8 (31.0–41.4) .052 (.038) .17 .26
EFSOCH 1,780 56.1 (54.2–58.1) 59.7 (57.5–62.0) 55.3 (50.8–60.2) .023 (.020) .25 .16
NFBC1966 4,453 53.6 (52.9–54.3) 53.7 (52.7–54.7) 55.7 (52.5–59.0) .007 (.010) .45 .99
Combined 7,549 .0009 (.008) .92 .75
HOMA-IR:
BCG 619 .89 (.84–1.06) .85 (.80–.91) .75 (.66–.84) .076 (.031) .01 .002
EFSOCH 1,780 1.15 (1.11–1.19) 1.23 (1.18–1.23) 1.14 (1.05–1.24) .025 (.019) .21 .14
NFBC1966 4,452 1.00 (.99–1.01) 1.00 (.99–1.01) 1.02 (.99–1.04) .004 (.004) .41 .95
Combined 6,851 .004 (.004) .35 1.00
Early insulin response (pmol/mmol/liter):
BCG 604 42.8 (40.0–45.9) 41.6 (38.6–44.8) 34.8 (30.1–40.3) .078 (.036) .03 .02
ALSPAC 631 33.0 (30.4–35.8) 30.4 (28.2–32..8) 31.6 (27.7–36.1) .055 (.039) .16 .27
Combined 1,235 .067 (.026) .01 .02
Disposition index (pmol2/liter2):
BCG 593 1,151.7 (1,011.3–1,310.3) 1,028.6 (894.3–1,182.0) 709.8 (541.9–929.8) .199 (.068) .004 .001
ALSPAC 591 849.8 (737.3–979.5) 648.1 (561.7–747.7) 639.7 (477.7–856.6) .184 (.072) .01 .03
Combined 1,184 .192 (.049) .0001 .0001
HbA1c (%):
ALSPAC 1,280 4.90 (4.87–4.92) 4.90 (4.87–4.92) 4.87 (4.81–4.92) .002 (.002) .41 .14
EFSOCH 1,442 5.06 (5.03–5.08) 5.07 (5.04–5.10) 5.04 (4.97–5.10) .0001 (.003) .97 .77
1958BC 1,813 5.20 (5.18–5.22) 5.21 (5.19–5.24) 5.25 (5.19–5.31) .004 (.003) .10 .07
Combined 4,535 .0001 (.001) .95 .35
NOTE.—All variables apart from fasting glucose were log-transformed before analysis. The per–T allele trait difference is presented as the logged value, but means and 95% CIs were
back-transformed. The combined values for each trait are from ﬁxed-effects inverse-variance meta-analysis. There was a large amount of heterogeneity among studies in the fasting insulin
and HOMA-IR analyses ( and 75%, respectively).2I p 68%
a Corrected for age, sex, and ln(BMI), except in ALSPAC, 1958BC, and NFBC1966, which were corrected for sex and BMI only, since subjects do not differ in age.
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30 g (95% CI 15–45 g) per risk allele. This result was seen
in ameta-analysis of three U.K. studies that included8,344
subjects and was independent of any fetal genotype effect.
Studies that have analyzed birth weight in relation to
the established type 2 diabetes gene variants—E23K in
KCNJ11 (MIM 600937) and Pro12Ala in PPARG (MIM
601487)—have found no evidence of association,56,57 al-
though, in the ﬁrst of these studies, maternal genotype
data were not reported. These variants may genuinely
have no effect on birth weight. However, it is possible that,
with the smaller type 2 diabetes risk conferred by these
variants (odds ratio ∼1.2) compared with TCF7L2 (odds
ratio ∼1.4), any effect on birth weight via alterations in
insulin secretion and action would be concordantly smaller
and would require a sample size of 110,000 individuals
for detection. Other studies have investigated the role of
common variation in genes that represent good biological
candidates for diabetes and related traits in relation to
birth weight.58 Positive associations with both diabetes-
related traits and birth weight have been shown for the
insulin gene (INS [MIM 176730]) variable number tan-
dem repeats (VNTR) locus,59–61 a microsatellite poly-
morphism in the insulin-like growth factor 1 gene (IGF1
[MIM 147440]),27,62 and a variant in the H19 gene (MIM
103280),63 but the former two have not been consistently
replicated,26,28–32,64 and the latter is currently the only study
of this gene in relation to common birth-weight variation.
Taken together, these results highlight the need for large
sample sizes and replication in the study of genetic as-
sociations between diabetes genes and fetal growth.
We previously studied the 30GrA (rs1799884) poly-
morphism in the glucokinase gene in two of the studies
with maternal DNA available, including the largest indi-
vidual study, ALSPAC.33,34 Presence of the A allele confers
a 0.06-mmol/liter increase in fasting glucose (95% CI
0.04–0.09 mmol/liter) across all ages in the normal pop-
ulation and, when carried by the mother, is associated
with an increase in offspring birth weight of 32 g (95%
CI 11–53 g).34 Combining information from these two
conﬁrmed common variants, we have shown that the 4%
of offspring born to mothers carrying three or four risk
alleles were 119 g (95% CI 62–172 g) heavier than the 32%
born to mothers with no risk alleles. This effect is similar
to the effect of mothers smoking 4–5 cigarettes per day in
the third trimester of pregnancy.65,66 It conﬁrms that com-
mon genetic variation can have a substantial effect on
birth weight.
To understand the mechanism that leads to the increase
in offspring birth weight, we studied 110,000 subjects,
which represents the largest study to date of the effect of
TCF7L2 genotypes on continuous traits related to type 2
diabetes. We found that the T allele at rs7903146 is as-
sociated with reduced insulin secretion when correcting
for insulin resistance (as measured by disposition index).
This supports the ﬁndings of previous studies of nondi-
abetic subjects.37,40,42,46 We also found a weaker association
with increased fasting glucose (per–T allele increase 0.020
[95% CI 0.005–0.035] mmol/liter). Results of analyses of
glucose concentrations from previous studies show either
an increase in fasting glucose or no change in glucose.37,
42,44,46 Our data suggest that the increase in birth weight
is likely to result from the risk allele reducing maternal
insulin secretion, which results in an increase in the preg-
nant maternal glycemia to which the fetus is exposed.
However, further studies in very large cohorts of pregnant
women will be needed to conﬁrm this, since most of our
data come from young adults, with only 921 females preg-
nant at the time of study.
To conclude, we have shown thatmaternal TCF7L2 type
2 diabetes–risk genotypes at rs7903146 are associatedwith
increased offspring birth weight, probably through im-
paired maternal insulin secretion. Together with the com-
mon GCK rs1799884 variant, TFC7L2 rs7903146 is asso-
ciated with differences in normal birth weight that are
comparable to those conferred by smoking, suggesting an
important role for genes in this complex trait.
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